What Is Medical Weed Used For? Evidence Explained

Search for medical weed and you will find two very different stories. Dispensary blogs list dozens of conditions it supposedly treats, from anxiety to cancer. Medical authorities tell a narrower, more careful story. The truth sits with the second group β€” and it is still more interesting than the hype suggests.

🌿 The short answer: Medical weed β€” cannabis used to treat a health condition β€” has its strongest evidence for chronic pain in adults, nausea and vomiting caused by chemotherapy, muscle spasticity in multiple sclerosis, and seizures in two rare childhood epilepsies (treated with purified CBD, not smoked cannabis). For most other conditions people ask about, including anxiety, depression, PTSD and sleep problems, the evidence is limited, mixed or missing. It is general information, not a recommendation β€” and it is not a substitute for talking to a clinician.

General information only β€” this article is not medical advice. It does not recommend cannabis for any condition. If you have a health condition, are pregnant or breastfeeding, or take prescription medicines, speak to a clinician before considering cannabis.

What is medical weed, exactly?

Medical weed β€” also called medical marijuana or medical cannabis β€” is cannabis used to treat the symptoms of an illness, rather than for recreation. The plant itself is not a medicine in the usual sense: the US Food and Drug Administration (FDA) has not approved the cannabis plant for any medical use. What regulators have approved is a small number of specific products containing individual cannabis compounds, each for a specific condition. That distinction matters, because most of what is sold as “medical weed” β€” flower, oils and edibles from a dispensary β€” has never been through the approval process a licensed medicine goes through.

The cannabis plant contains around 540 chemical substances, including more than 100 cannabinoids, according to the US National Center for Complementary and Integrative Health (NCCIH). The two that do most of the work are THC (delta-9-tetrahydrocannabinol), which is intoxicating and produces the high, and CBD (cannabidiol), which is not intoxicating. Most medical cannabis products are some combination of the two, and the ratio shapes the experience: high-THC products carry more risk of anxiety, paranoia and impairment, while CBD-dominant products are generally gentler β€” though, as our guide to how CBD actually feels explains, CBD on its own is subtle and is not a proven treatment for anxiety, sleep or pain. The strains of weed and their effects also vary far more by their THC and CBD content than by whether they are labelled indica or sativa.

Medical cannabis can be inhaled, taken by mouth as an oil, capsule or edible, placed under the tongue as a tincture, or applied to the skin. The form matters: smoked or vaped cannabis acts within minutes, oils take longer, and edibles can take one to two hours to peak β€” which is why dose control is hardest with edibles. In the UK, prescribed cannabis flower is prescribed for vaporisation, not smoking.

It is also worth being clear about what “medical” means on a dispensary shelf. In many US states, a medical card is a legal route to buying cannabis, and the qualifying conditions are set by state law, not by the strength of the evidence. A condition appearing on a state’s qualifying list is a legal fact, not a medical endorsement. The evidence is a separate question β€” and it is the one this article answers.

What is medical weed used for? The uses with the strongest evidence

The most thorough review of the evidence remains the 2017 report from the National Academies of Sciences, Engineering, and Medicine, The Health Effects of Cannabis and Cannabinoids, which weighed more than 10,000 scientific abstracts and reached nearly 100 conclusions. Its verdict was narrow: there was conclusive or substantial evidence of benefit for only three uses. Later reviews summarised by the NCCIH and the Mayo Clinic have not widened that list much. Here are the uses that clear the bar, strongest first.

Chronic pain in adults

This is the most common reason people use medical cannabis, and the best-supported one β€” with an important caveat about size. The National Academies found substantial evidence that cannabis or cannabinoids help adults with chronic pain, and that treated patients were more likely to experience a clinically significant reduction in pain. But the effect is modest. A 2018 review of 47 studies involving 4,743 people, summarised by the NCCIH, found that 29% of people taking cannabis or cannabinoids had at least a 30% reduction in pain, compared with 26% of those taking a placebo β€” a real difference, but a small one, and side effects were more common in the cannabis groups. The evidence is strongest for neuropathic pain β€” the shooting or burning pain caused by nerve damage, which people with conditions such as HIV or diabetes may experience. It is not evidence that cannabis replaces other pain treatments, and the NCCIH notes that high-quality studies have not shown that cannabinoids let people reduce their opioid dose.

Nausea and vomiting caused by chemotherapy

This is the use with the most conclusive evidence. The National Academies found conclusive evidence that oral cannabinoids are effective antiemetics β€” drugs that prevent or treat nausea and vomiting β€” for chemotherapy-induced nausea and vomiting. The Mayo Clinic agrees: research has shown that THC helps lessen nausea and vomiting in people receiving chemotherapy, particularly when standard anti-sickness medicines have not worked. Two licensed medicines exist for exactly this purpose: dronabinol (Marinol) and nabilone (Cesamet), both synthetic THC-based drugs approved by the FDA. In the UK, nabilone is one of only three licensed cannabis-based medicines, prescribed for chemotherapy sickness when other options have not worked or are not suitable.

Muscle spasticity in multiple sclerosis

Spasticity β€” muscle stiffness and spasms that a person cannot control β€” is the third use with substantial evidence behind it. The National Academies found substantial evidence that oral cannabinoids improve patient-reported spasticity symptoms in people with multiple sclerosis, though the improvement did not show up as clearly on clinician-measured tests. A review of 17 studies involving 3,161 people, summarised by the NCCIH, found small improvements in patient-reported spasticity, pain and bladder problems. The licensed mouth spray nabiximols (Sativex), which contains THC and CBD in roughly equal amounts, is approved in more than 25 countries outside the United States for MS spasticity, and in the UK it is prescribed for MS muscle stiffness when other options have not worked.

Seizures in rare childhood epilepsies

This is the most clear-cut medical use of any cannabis-derived product β€” and the one most often misunderstood. The FDA has approved Epidiolex, a purified liquid form of CBD, for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two rare and severe forms of childhood epilepsy, and later for tuberous sclerosis complex, in patients aged one year and older. In the trial published in the New England Journal of Medicine in 2017 (Devinsky et al.), median convulsive-seizure frequency in Dravet syndrome fell by 39% on cannabidiol, compared with 13% on placebo. That is a pharmaceutical product, made to a fixed strength and purity and taken at a dose set by a doctor. It is not evidence that smoked cannabis, shop-bought CBD oil or an edible helps epilepsy: the NCCIH states that not enough research has been done on cannabinoids for other, more common forms of epilepsy to reach conclusions about whether they help.

Appetite and weight loss in HIV/AIDS

Dronabinol has been FDA-approved since 1992 for loss of appetite associated with weight loss in people with HIV/AIDS, based primarily on a study of 139 people. Beyond that approval, the evidence is limited: the few other studies were short, small and possibly biased, and the National Academies found only limited evidence for increased appetite in HIV. This is a use with a licensed medicine behind it, not a use with broad evidence for cannabis itself.

Condition Evidence strength What it means in practice
Chronic pain in adults Substantial β€” modest benefit More likely than placebo to give a meaningful pain reduction, especially nerve pain; the average gain over placebo is small
Chemotherapy-induced nausea and vomiting Conclusive (oral cannabinoids) The best-proven use; licensed drugs dronabinol and nabilone exist for it
MS spasticity (patient-reported) Substantial Patients report less stiffness and fewer spasms; clinician-measured improvement is less clear
Rare childhood epilepsy (Dravet, Lennox-Gastaut) FDA-approved medicine (purified CBD) Epidiolex only β€” not smoked cannabis or shop CBD oil
HIV-related appetite and weight loss Limited Dronabinol is licensed for it; evidence for cannabis itself is thin
Sleep disturbance linked to chronic illness Moderate (short-term) Better sleep reported alongside pain or MS, but unclear whether sleep itself or the symptoms improved
Anxiety Insufficient / limited One small study (24 people) found less anxiety in a public-speaking test on CBD; no basis for treating anxiety disorders
PTSD Insufficient One very small study (10 people) of nabilone for nightmares; observational studies give no clear answer
Glaucoma Limited evidence of no benefit Cannabis lowers eye pressure only briefly and less effectively than existing treatments
Cancer treatment Insufficient Some animal studies show promise; no large studies show cannabis treats cancer
Inflammatory bowel disease (Crohn’s, ulcerative colitis) Insufficient A 2018 review of 3 small Crohn’s studies (93 people) found no difference from placebo in remission

What about anxiety, sleep, PTSD and the other common claims?

Most of the conditions on dispensary lists sit in this section: widely claimed, weakly evidenced. That does not mean nobody benefits β€” it means the research has not shown it, and the claims run ahead of the data.

Anxiety. This is the claim most likely to mislead, because it cuts both ways. The NCCIH summary is blunt: a small amount of evidence from studies in people suggests cannabinoids might help reduce anxiety, resting largely on one study of 24 people with social anxiety disorder who felt less anxious in a simulated public-speaking test after CBD than after a placebo. That is not a treatment for an anxiety disorder. Meanwhile, cannabis can also increase anxiety β€” particularly at high doses, with high-THC products, or in people new to it. Our guide to whether indica or sativa is better for anxiety reaches the same conclusion from the strain side: dose and THC-to-CBD ratio matter far more than the label on the jar, and for some people cannabis makes anxiety worse, not better. Anxiety disorders have evidence-based treatments β€” therapy and, where appropriate, prescribed medication β€” with far stronger support than cannabis.

Sleep. Many studies of cannabis in people with health problems such as MS, PTSD or chronic pain have found better sleep quality or fewer sleep disturbances. The catch, noted by the NCCIH, is that it is uncertain whether cannabis affected sleep directly, or whether people simply slept better because their pain or other symptoms had improved. The National Academies found only moderate evidence for improved short-term sleep in people whose sleep problems were linked to conditions such as sleep apnoea, fibromyalgia, chronic pain or MS. For sleep problems in people without another illness, the effects are uncertain β€” cannabis is not a proven sleep aid.

PTSD. Some people with PTSD use cannabis and believe it helps, but there has been little research on whether it actually does. The NCCIH cites one very small study β€” 10 people β€” in which the cannabinoid nabilone worked better than a placebo at relieving PTSD-related nightmares, and observational studies that give no clear evidence either way. The National Academies found insufficient evidence to support or refute cannabis for PTSD.

Depression. There is no good evidence that cannabis treats depression, and the National Academies found moderate evidence linking cannabis use to a small increased risk of depression. Using cannabis to manage low mood is a pattern worth discussing with a clinician, not a treatment plan.

Glaucoma. Cannabis can lower pressure in the eye, which sounds promising β€” but studies from the 1970s and 1980s showed it did so less effectively than treatments already in use, and only for a few hours at a time. The NCCIH concludes that cannabis is not helpful for glaucoma, and the Mayo Clinic notes that it may even reduce blood flow to the optic nerve. This is a use where the folk claim has been tested and found wanting.

Cancer. Some people use cannabis hoping to treat their cancer itself. Animal studies show some promise, but as the Mayo Clinic states, there are no large studies showing that cannabis helps treat cancer, and more research is needed. Managing chemotherapy sickness is a proven use; treating the cancer is not.

Inflammatory bowel disease and irritable bowel syndrome. A 2018 review of 3 studies involving 93 people with active Crohn’s disease found no difference between cannabis or cannabis oil and placebo in clinical remission, though some people reported symptom improvements alongside side effects. For ulcerative colitis, two small studies found no difference in remission with CBD capsules. For IBS, there has been so little research in people that it is unknown whether cannabis helps at all.

How is medical weed taken β€” and what are the risks?

Medical cannabis is not risk-free, and the risks are dose-related: the higher the THC dose, the worse the side effects tend to be. The Mayo Clinic lists the common ones as headaches, dry mouth, red and dry eyes, dizziness and a higher risk of falling, drowsiness and problems focusing, fatigue, coughing and wheezing. Other reported effects include nausea and vomiting, anxiety, hallucinations and psychosis, memory problems, and a fast or irregular heartbeat. Doses of CBD above 300 mg a day can cause nausea, vomiting, diarrhoea and liver problems. Cannabis also affects attention and movement β€” do not drive or use machinery while using it.

Three risks deserve more than a passing mention. First, dependence: cannabis can be habit-forming, and regular users can develop cannabis use disorder and withdrawal symptoms including insomnia, sweating, stomach pain, anger and mood changes. Second, mental health: the National Academies found substantial evidence of an increased risk of schizophrenia among frequent users, particularly people already at risk, and moderate evidence of a small increased risk of depression and social anxiety disorder. People with bipolar disorder may find cannabis makes them irritable or restless, and research in people with schizophrenia suggests it may raise the risk of psychosis. Third, interactions: cannabis can interact with alcohol, blood thinners such as warfarin, medicines that depress the central nervous system, and seizure medicines β€” and CBD affects liver enzymes that process many common drugs. The Mayo Clinic advises reviewing all medicines with a healthcare professional or pharmacist before using cannabis, and avoiding it for two weeks before general anaesthesia, since it can raise anaesthetic requirements and the risk of complications.

Pregnancy and breastfeeding are clear no-go areas: regulators advise against cannabis use in both, because its effects on a developing baby have not been established, and use in pregnancy is linked to babies being born early or at a low birth weight. People with active heart disease, active mental health disorders or a history of substance misuse should also avoid it, according to the Mayo Clinic.

One practical point about product quality: a licensed medicine contains a known dose of a known compound. Dispensary flower and oils vary between batches, and independent testing has repeatedly found products containing more THC β€” or far less CBD β€” than their labels state. If a product labelled CBD makes you feel high, it probably contains more THC than claimed.

Is medical weed legal, and how do people get it?

The law depends entirely on where you live, and it changes often β€” so treat anything below as a snapshot, and check the current rules for your own country or state.

In the UK, medical cannabis has been legal on prescription since November 2018, but only a specialist doctor β€” one on the General Medical Council’s Specialist Register β€” can prescribe it; a GP cannot start a prescription. On the NHS, access is limited to three licensed medicines: Epidyolex for rare forms of epilepsy, Sativex for MS muscle stiffness, and nabilone for chemotherapy sickness. The National Institute for Health and Care Excellence (NICE) does not recommend THC, THC combined with CBD, nabilone or dronabinol for chronic pain in adults. Most UK patients who use cannabis-based medicines do so through private clinics, and cannabis without a prescription β€” including THC-containing oil β€” remains illegal whatever the reason for using it.

In the United States, the picture is split by state. Many states have medical cannabis programmes with their own qualifying-condition lists, registration systems and purchase limits, while cannabis remains illegal under federal law β€” and the FDA has not approved the cannabis plant as a medicine. Our guide to whether medical weed is legal in Florida shows how strict a state programme can be: patients need a qualifying condition, a certification from a state-registered physician and a registry ID card, and recreational use stays illegal. Florida does not recognise medical cards from other states, and neither do most states β€” a card is not a passport.

Wherever you are, the process is broadly similar: a clinician assesses you, confirms a qualifying condition, and β€” if they judge it appropriate β€” certifies or prescribes. Beware of services that promise a card for any condition with no real assessment: a recommendation made without a proper consultation is a red flag, not a shortcut.

Should you consider medical weed?

The honest answer depends on what you are hoping it will do. If you have chronic pain, chemotherapy sickness or MS spasticity that has not responded to standard treatments, there is real β€” if modest β€” evidence that a cannabinoid medicine might help, and that is a conversation worth having with your clinician. If you are considering it for anxiety, depression, PTSD, insomnia or cancer itself, the evidence does not support it as a treatment, and the treatments that do have evidence behind them deserve the first try.

A few questions to take to that conversation: which licensed medicine, if any, fits your condition β€” a purified product such as Epidiolex or nabilone, or a THC:CBD spray such as nabiximols? What dose would you start at, and how would you and your clinician judge whether it is working? What medicines do you already take that could interact? And what would make you stop β€” side effects, no benefit after a set trial period, or a worsening of your symptoms? A clinician who cannot answer those questions is not the right person to guide you.

Finally, keep expectations in proportion. Even for the best-supported use, chronic pain, the average benefit over placebo in the largest review was small β€” a few more people in a hundred reaching a meaningful reduction. Medical cannabis helps some people, modestly, for a small number of problems. Anyone promising more than that is selling something, not summarising the science.

This article is general information, not medical advice. If you are considering cannabis for a health condition, talk to a clinician first β€” especially if you are pregnant or breastfeeding, take prescription medicines, or have a mental health condition or a history of substance misuse.

Frequently asked questions

What is medical weed used for?

Medical weed is used mainly for chronic pain in adults, nausea and vomiting caused by chemotherapy, muscle spasticity in multiple sclerosis, and seizures in rare childhood epilepsies (with purified CBD, not smoked cannabis). It is also prescribed in some places for appetite loss in HIV/AIDS and for other conditions, but the evidence for most other uses is limited or missing.

What conditions qualify for medical weed?

Qualifying conditions are set by law, not by evidence, so they vary by place. Common lists include chronic pain, cancer, epilepsy, multiple sclerosis, PTSD, glaucoma, HIV/AIDS, Crohn’s disease and Parkinson’s disease. In the UK, NHS prescribing is limited to three licensed medicines for specific conditions; in US states, the list is set by each state’s programme. A condition being on a list does not mean cannabis is proven to treat it.

Does medical weed help with chronic pain?

Yes, modestly β€” this is the best-supported use. The National Academies found substantial evidence that cannabis or cannabinoids help adults with chronic pain, especially nerve pain. But the effect is small: in a 2018 review of 47 studies, 29% of people on cannabis or cannabinoids had at least a 30% pain reduction, compared with 26% on placebo. It is not a replacement for other pain treatments.

Is medical weed good for anxiety?

There is no good evidence that it is. One small study of 24 people found less anxiety in a public-speaking test after CBD, but that is not evidence for treating an anxiety disorder. Cannabis can also make anxiety worse, especially at high doses or in high-THC products. Evidence-based anxiety treatments have far stronger support.

Can medical weed help with sleep?

Possibly, but only indirectly and only in the short term. People with chronic pain, MS or PTSD who used cannabis reported better sleep, but it is unclear whether their sleep improved directly or because their other symptoms eased. For sleep problems without another illness, the effects are uncertain. Cannabis is not a proven sleep aid.

Sources

  • National Academies of Sciences, Engineering, and Medicine (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press. doi: 10.17226/24625. https://pubmed.ncbi.nlm.nih.gov/28182367 (Bookshelf ID NBK423845; reviewed more than 10,000 abstracts; conclusive/substantial evidence for chronic pain, chemotherapy-induced nausea and vomiting, and patient-reported MS spasticity)
  • Mayo Clinic (2025). Marijuana. Updated 15 August 2025. https://www.mayoclinic.org/drugs-supplements-marijuana/art-20364974 (FDA-approved cannabinoid medicines; uses by condition; side effects, interactions and cautions)
  • National Center for Complementary and Integrative Health (NCCIH). Cannabis (Marijuana) and Cannabinoids: What You Need To Know. https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know (2018 reviews: 47 chronic-pain studies, 4,743 participants; Crohn’s, PTSD, glaucoma, MS and sleep summaries; dronabinol’s 1992 HIV approval)
  • Devinsky, O. et al. (2017). Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England Journal of Medicine, 376(21), 2011–2020. (Median convulsive-seizure frequency fell 39% on cannabidiol vs 13% on placebo; Epidiolex FDA approval 25 June 2018.)
  • UK legal position: medical cannabis legal on prescription since 1 November 2018, specialist doctors only; NHS use limited to Epidyolex, Sativex and nabilone; NICE does not recommend THC-based products for chronic pain. Summarised from NHS guidance in: https://evopure.co.uk/medical-cannabis-uk/ (accessed 19 Nov 2026).

Last updated: 19 November 2026. This article is general information, not medical advice. If you are considering cannabis for a health condition, speak to a clinician first.

Leave a Reply

Your email address will not be published. Required fields are marked *